FinCanna Capital Corp. (“FinCanna”) (CSE:CALI)(OTCQB:FNNZF), a royalty company for the U.S. licensed medical cannabis industry announces the closing of its Convertible Debenture Financing for $2.5 million

The subscription price is $1,000 per Unit. The Debentures will mature on February 8, 2023 and will bear interest at 12% per annum, payable in cash or, at the option of the Subscriber, in common shares of FinCanna subject to certain conditions. The Debenture is convertible into Common Shares at CAD$0.15 per share. Subscribers for Debentures will receive 5,000 common share purchase warrants for each Unit of principal amount of Debenture. Each Warrant will entitle the holder to acquire one Common Share of FinCanna for CAD$0.30 at any time up to the maturity date.


The FinCanna management team subscribed for $500,000 principal amount of the Debentures.

FinCanna intends to use the net proceeds from the Convertible Debenture to fund ongoing working capital and general corporate purposes as well selective royalty investment opportunities.

“We are very encouraged by the strong support from several key debenture holders, shareholders and management,” said Andriyko Herchak, CEO of FinCanna Capital. “These additional funds together with the previously announced extension of the convertible debentures, now maturing in February 2023, have significantly strengthened our balance sheet at a time when our investees are ramping up their sales and royalties for FinCanna, which we believe will have very meaningful impact to our bottom line.”

This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

The Canadian Securities Exchange has in no way passed upon the merits of the amendments to the terms of the outstanding Convertible Debentures and Warrants and new Convertible Debenture Financing and has neither approved nor disapproved the contents of this press release.

About FinCanna Capital Corp.

FinCanna is a royalty company that provides growth capital to rapidly emerging private companies operating in the licensed U.S cannabis industry. The company earns its revenue from royalties paid by its investee companies that are calculated based on a percentage their total revenues.

FinCanna’s scalable royalty model provides an attractive alternative or complement to debt or equity financing for its investee companies. FinCanna is focused on delivering high impact returns to its shareholders by way of a strategically diversified investment portfolio.

For additional information visit www.fincannacapital.com and FinCanna’s profile at www.sedar.com

FinCanna Capital Corp.
Andriyko Herchak, CEO & Director

Investor Relations:
Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Forward-Looking Information

This news release contains forward-looking information based on current expectations. Statements about, among other things, the use of proceeds of the Convertible Debenture financing, is forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. Such factors include but are not limited to the Company may not use the proceeds of the Convertible Debenture financing as currently anticipated. Although such statements are based on management’s reasonable assumptions at the date such statements are made, actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. FinCanna assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

SOURCE: FinCanna Capital Corp.

View source version on accesswire.com:
https://www.accesswire.com/596477/FinCanna-Closes-25-Million-Convertible-Debenture-Financing

ACCESSWIRE
July 7, 2020 – 5:00 AM PDT
News by QuoteMedia

HempFusion Wellness Inc . (TSX:CBD.U) (US:CBDHF) (FWB:8OO) (“ HempFusion ” or the “ Company ”), a leading health and wellness company offering premium probiotic supplements and products containing CBD, announced today it will report its financial results for the first quarter ended March 31, 2021 at 4 p.m., Eastern Time, on Monday, May 17, 2021 followed by a 4:15 p.m., Eastern Time conference call and webcast with a question-and-answer session.

To participate in the call, please dial 888-506-0062. For international callers, dial 973-528-0011. Use Participant Code: 795055

Keep reading... Show less

Partnership Aimed at Delivering Psychedelic
Capsule for Dosing Study in Human Clinical Trial

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, and Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, have met another early milestone in the development of an initial all natural psilocybin extract.

Keep reading... Show less

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, and Numinus Wellness Inc. (“Numinus“) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, have met another early milestone in the development of an initial all natural psilocybin extract.

Optimi and Numinus, through Impact Clinical Trials Accelerator at the University of Calgary (“Impact”), have submitted a pre-clinical trial application to Health Canada for review and comment. Meanwhile, cultivation, research, formulation, and continuous validation studies to produce the investigational psilocybin extract for trial continue at the Health Canada-licensed Numinus lab in British Columbia, Canada.

Keep reading... Show less

Poised for Rapid Growth in Europe’s Largest Medical Cannabis Market

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) (“Curaleaf” or the “Company”) a leading international provider of consumer products in cannabis, today announced that wholly owned Curaleaf International subsidiary Adven GmbH (“Adven”) has launched its own range of medical cannabis products in Germany Europe’s largest medical cannabis market.  The initial launch of a high THC oil product aims to meet immediate patient demand and will be extended over the course of the year to incorporate a number of different strengths and THCCBD formulations in both oil and flower formats, addressing a wide range of patient needs. Germany is Europe’s largest medical cannabis market and is expected to be worth US$2.1 billion by 2025 1 .

Keep reading... Show less

After announcing placements of Fit Soda™ in well-known regional grocery chains such as HEB and Sprouts, Koios is pleased to announce that its Fit Soda™ functional beverage is now available in all Food Lion supermarkets, a chain which operates more than 1,100 grocery stores in the eastern United States. As the sugar-free beverage category continues to grow, Coca-Cola recently announced its prediction that its “Coke Zero Sugar” variety will be the firm’s biggest driver of growth in 2021 and beyond. Based on these industry trends, Koios’ objective is to strategically grow the market presence of Fit Soda™, which sold approximately 700,000 units in 2020, its first full calendar year on the market.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that as of Monday, May 10, 2021 all four flavours of Fit Soda ™ are being carried in more than 1,100 supermarkets operated by Food Lion LLC (“Food Lion”), a multistate grocery chain based in Salisbury, North Carolina. Since November 2020, the Company has placed its Fit Soda ™ functional beverage product with several other regional chains across the United States to include HEB (as announced in a November 4, 2020 press release), all three banners of Massachusetts-based Roche Bros. (as announced in a February 24, 2021 press release), and Sprouts Farmers Market (as announced in a March 4, 2021 press release). Approximately 700,000 units of Fit Soda ™ were sold during the product’s first full calendar year of retail sales in 2020 between retail placements in grocery and foodservice outlets, as well as direct-to-consumer sales through the Koios online store. With the addition of Fit Soda ™ to all 1,100 locations of Food Lion across ten U.S. states, the Company believes there is significant opportunity for Fit Soda ™ to have its best year yet in 2021.

Keep reading... Show less